Medicine (Baltimore). 2018 Nov;97(46):e12662. doi: 10.1097/MD.0000000000012662.
Li J1, Chen N2, Wang D1, Zhang J2, Gong X1.
1 Department of Gastroenterology.
2 Department of General Medicine, the First Affiliated Hospital of Jinan University, Guangzhou, China.
This study appears to be unaware that poor guts need a gut-friendly form of vitamin D
Overview Gut and vitamin D has the following summary
- Gut problems result in reduced absorption of Vitamin D, Magnesium, etc.
- Celiac disease has a strong genetic component.
- Most, but not all, people with celiac disease have a gene variant.
- An adequate level vitamin D seems to decrease the probability of getting celiac disease.
- Celiac disease causes poor absorption of nutrients such as vitamin D.
- Bringing the blood level of vitamin D back to normal in patients with celiac disease decreases symptoms.
- The prevalence of celiac disease, not just its diagnosis, has increased 4X in the past 30 years, similar to the increase in Vitamin D deficiency.
- Review in Nov 2013 found that Vitamin D helped
- Many intervention clinical trials for vitamin D to prevent or treat Gut problems (93 trials listed as of Jan 2017)
- All items in category gut and vitamin D
Overview Gut and vitamin D contains gut-friendly informationGut-friendly, Sublingual, injection, topical, UV, sunshine
Getting Vitamin D into your body has the following chart
Getting Vitamin D into your body also has the following
Bio-D-Mulsion Forte – especially made for those with poorly functioning guts, or perhaps lacking gallbladder
Sublingual – goes directly into bloodstream
Oil: 1 drop typically contains 400 IU, 1,000 IU, or 4,000 IU, typically not taste good
Topical – goes directly into bloodstream. Put oil on your skin, Use Aloe vera cream with Vitamin D, or make your own
Vaginal – goes directly into bloodstream. Prescription only?
Bio-Tech might be useful – it is also water soluble
Vitamin D sprayed inside cheeks 2X more response (poor gut) – RCT Oct 2015
and, those people with malabsorption problems had a larger response to spray
Inject Vitamin D quarterly into muscle, into vein, or perhaps into body cavity if quickly needed
Nanoparticles could be used to increase vitamin D getting to the gut – Oct 2015
Liposomal form on Amazon - Dec 2015
$20 for 60 servings of 2500 IU - unsure why a very low-cost gut-friendly form should not be used instead
Poor guts need different forms of vitamin D has the following
Guesses of Vitamin D response if poor gut
Bio Form Speed Duration 10 Injection: Vitamin D,
or Calcidiol or Calcitriol
Fast Long 10 Sun/UV Slow Long 10 Topical
(skin patch/cream, vagina)
Slow Normal 9? Inhaled (future) Fast Normal 8 Bio-D-Mulsion Forte Normal Normal 6 Water soluble (Bio-Tech) Normal Normal 5 Nanoemulsion
perhaps activates VDR
Normal Normal 4 Sublingual/spray
(some goes into gut)
Fast Normal 3 Coconut oil based Slow Normal 2 Food (salmon etc.) Slow Normal 2 Olive oil based (majority) Slow Normal
10= best bioavailable, 0 = worst, guesses have a range of +-2
Speed: Fast ~2-6 hours, Slow ~10-30 hours
Duration: Long ~3-6 months, Normal = ~2 months
Gut category listing contains the following
131 items in GUT category - see also Overview Gut and vitamin D,
- "Ulcerative Colitis" OR UC 689 items March 2019
- "celiac disease" OR CD 1280 items Feb 2018
- "inflammatory bowel disease" OR "inflammatory bowel symptom" 1010 items as of March 2019
- Crohn's 1230 items as of Feb 2019
- Gut-Friendly forms of vitamin D
such as: bio-emulsion, topical, spray, sublingual, inhaled, injection . .
Vitamin D (VitD) deficiency is prevalent in patient with inflammatory bowel disease (IBD). Recent studies have found that VitD can induce and maintain IBD remission through antibiosis, anti-inflammatory, and repair of intestinal mucosal barriers, thus improving the patient's disease activity and quality-of-life. The purpose of this meta-analysis is to evaluate the therapeutic effect and safety of VitD in the treatment of IBD.
Published randomized controlled trials (RCTs) were included from electronic databases (PubMed, Embase, Cochrane library, Web of Science, and so forth). Cochrane handbook was applied to evaluate the methodological quality. The levels of 25(OH)D3, relapse rate, inflammation index, and adverse events were compared between the experimental group and the control group (placebo group). All statistical analyses were directed by Revman 5.3 software and statistical significance was defined as P < .05.
Eighteen RCTs involved 908 patients were included. Meta-analysis showed that VitD improved the 25(OH)D3 levels more significantly than the control group (ng/mL, weighted mean deviation [WMD] = 7.85, 95% CI (5.52, 10.18), P < .000001), and compared with lower doses, there were significant differences increasing 25(OH)D3 levels (WMD = 11.19, 95% CI [4.73, 17.65], P = .0007) in high-dose VitD treatment while there was no significant difference in the adverse events between 2 groups (WMD = 1.56, 95% CI [0.74, 3.29], P = .24).
VitD reduced the relapse rate more significantly than the control group, but there were no significant differences between the low-dose and high-dose vitamin D treatment. The erythrocyte sedimentation rate (ESR) and high-sensitivity C-reactive protein (hsCRP) of the VitD and the control group showed no statistically significant difference (ESR [mm/h]: WMD = -0.22, 95% CI [-5.73, 5.29], P = .94; hsCRP (mg/dL): WMD = -0.53, 95% CI [-1.68, 0.62], P = .37).
The treatment of VitD in patients with IBD can improve the level of 25(OH)D3 and control the relapse rate of the disease, whose clinical curative effect is more accurate. Thus VitD should be recommended for the treatment of IBD, at least as an adjunctive treatment.